Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

PALOMA-3 (ClinicalTrials.gov identifier: NCT05388669) is a phase III, international, randomized trial assessing the noninferiority of pharmacokinetics, efficacy, and safety of subcutaneous versus ...

GSK’s follow-up to severe asthma therapy Nucala, depemokimab, clears two phase 3 trials, reducing attacks compared to placebo with six-monthly dosing.

Dementia refers to a category of diseases that causes loss of memory and other mental functions. There are three stages.